Publications by authors named "Stephanie Troy-Fioramonti"
Article Synopsis
- Researchers developed JM-00266, a new cannabinoid 1 receptor (CB1R) blocker with limited ability to cross the blood-brain barrier, aimed at treating metabolic disorders linked to obesity.
- Unlike its predecessor Rimonabant, JM-00266 does not affect central behaviors like food intake and anxiety, indicating it primarily acts in the periphery.
- JM-00266 enhances glucose tolerance and insulin sensitivity in mice and promotes fat breakdown in adipose tissue, suggesting its potential for managing obesity-related metabolic issues.
Article Synopsis
- Research shows that obesity leads to overactivation of the endocannabinoid system (ECS), which impacts metabolism in fat tissue through cannabinoid receptor 1 (CB1R).
- Experiments in mice and rat fat tissue revealed that activating the ECS increases glycerol release related to fat breakdown, but this effect depends on insulin levels and the presence of CB1R.
- The findings suggest a link between CB1R activation and alterations in fat metabolism, indicating a potential role in obesity-related conditions and the need for further investigation.
Evidence suggests that alterations of glucose and lipid homeostasis induced by obesity are associated with the elevation of endocannabinoid tone. The biosynthesis of the two main endocannabinoids, N-arachidonoylethanolamine and 2-arachidonoyl-glycerol, which derive from arachidonic acid, is influenced by dietary fatty acids (FAs). We investigated whether exposure to n-3 FA at a young age may decrease tissue endocannabinoid levels and prevent metabolic disorders induced by a later high-fat diet (HFD) challenge.
View Article and Find Full Text PDFArticle Synopsis
- The endocannabinoid system (ECS) influences glucose levels, specifically through cannabinoid receptor-1 (CB1R) activation, but its impact on intestinal glucose absorption is not well understood.
- In a study, mice given anandamide showed improved high blood sugar after glucose was consumed, but glucose clearing and insulin sensitivity were negatively affected, indicating changes in gut function.
- The decrease in gut movement caused by anandamide was reversed when using CB1R and CB2R blockers, and the findings suggest that the ECS reduces blood sugar levels after eating by slowing down gastric emptying and intestinal movement, rather than affecting how glucose is absorbed.